RECRUITINGPhase 4INTERVENTIONAL

Ensuring Access to Optimal Therapy in CF: The ENACT Study

Ensuring Access to Optimal Therapy in Cystic Fibrosis: The ENACT Study

About This Trial

This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

Who May Be Eligible (Plain English)

Who May Qualify: - documentation of CF diagnosis per CFF diagnostic criteria and known CFTR genotype - age 2 years and older - ability to provide written willing to sign a consent form and/or assent (by subject and/or legal guardian) - on a stable dose of triple combination CFTR modulator therapy for at least two weeks prior to Visit 1 - clinically stable lung disease, defined as no documented acute decrease in FEV1 \> 10%, OR use of additional antibiotics (intravenous \[IV\] or oral \[PO\]) within 4 weeks prior to screening Who Should NOT Join This Trial: - recent significant unintentional weight loss, as determined by the investigator, in the 4 weeks prior to screening - pregnant or breastfeeding female - history of alcohol or substance abuse in the 6 months prior to screening - participation in a study involving an investigational intervention within 28 days (or 5 half-lives, whichever is longer) prior to screening - in the opinion of the Investigator, medical or psychiatric illness, or other conditions that would interfere with participation Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * documentation of CF diagnosis per CFF diagnostic criteria and known CFTR genotype * age 2 years and older * ability to provide written informed consent and/or assent (by subject and/or legal guardian) * on a stable dose of triple combination CFTR modulator therapy for at least two weeks prior to Visit 1 * clinically stable lung disease, defined as no documented acute decrease in FEV1 \> 10%, OR use of additional antibiotics (intravenous \[IV\] or oral \[PO\]) within 4 weeks prior to screening Exclusion Criteria: * recent significant unintentional weight loss, as determined by the investigator, in the 4 weeks prior to screening * pregnant or breastfeeding female * history of alcohol or substance abuse in the 6 months prior to screening * participation in a study involving an investigational intervention within 28 days (or 5 half-lives, whichever is longer) prior to screening * in the opinion of the Investigator, medical or psychiatric illness, or other conditions that would interfere with participation

Treatments Being Tested

DRUG

Elexacaftor / Ivacaftor / Tezacaftor

This study will examine different dosing strategies and outcomes for triple combination CFTR modulator therapy using the drug(s) elexacaftor, tezacaftor, and/or ivacaftor in patients with cystic fibrosis.

OTHER

therapeutic drug monitoring

Participants who consent to the therapeutic drug monitoring study will have their dose adjusted to remain within estimated effective concentrations.

Locations (2)

Arkansas Children's Hospital

Little Rock, Arkansas, United States

University of Washington

Seattle, Washington, United States